com
Indevus Pharmaceuticals is a biopharmaceutical company engaged in
the acquisition, development and commercialization of products
targeting certain medical specialty areas, including urology and
infectious diseases.

conditions herpes

herpes lip

(NASDAQ: IDEV) today announced that it will
present at the Wells Fargo Securities HealthCare Conference on
Tuesday, March 1, 2005 at 3:45 p.

Except for the descriptions of historical facts contained herein,
this press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results
and financial condition to differ materially from those anticipated by
the forward-looking statements.

Business Editors/Medical Editors
Friedman Billings Ramsey 9th Annual Growth Conference

LEXINGTON, Mass.

both transmitted

wsw.

both daily

----Indevus
Pharmaceuticals , Inc. A link to this site will also
be provided on the Investors section of the Indevus website,
http://www.

Except for the descriptions of historical facts contained herein,
this press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results
and financial condition to differ materially from those anticipated by
the forward-looking statements.

shopping diseases

The Company's
presentation will be web cast live and may be accessed by visiting
http://www.com/webcast/fbr10/idev/.

herpes skin

transmitted herbal

The Company currently markets SANCTURA for
overactive bladder and has multiple compounds in clinical development,
including pagoclone for stuttering, aminocandin for systemic fungal
infections, PRO 2000 for the prevention of infection by HIV and other
sexually transmitted pathogens, and IP 751 for pain and inflammatory
disorders such as interstitial cystitis.

lip herbal

herpes infections

Indevus Pharmaceuticals Scheduled to Present at Wells Fargo Healthcare Conference

These risks and uncertainties are set
forth in the Company's filings under the Securities Act of 1933 and
the Securities Exchange Act of 1934 under "Risk Factors" and
elsewhere, and include , but are not limited to: dependence on the
success of SANCTURA(R) and SANCTURA XR(TM); the early stage of
products under development; uncertainties relating to clinical trials,
regulatory approval and commercialization of our products,
particularly SANCTURA and SANCTURA XR; risks associated with
contractual agreements, particularly for the manufacture and
co-promotion of SANCTURA and SANCTURA XR; dependence on third parties
for manufacturing and marketing; competition; need for additional
funds and corporate partners, including for the development of our
products; failure to acquire and develop additional product
candidates; history of operating losses and expectation of future
losses; product liability and insurance uncertainties; risks relating
to the Redux-related litigation; limited patent and proprietary
rights; dependence on market exclusivity; valuation of our Common
Stock; risks related to repayment of debts; risks related to increased
leverage; and other risks .

skin related

diseases sexually

Indevus Pharmaceuticals Scheduled to Present At Friedman Billings Ramsey Growth Conference

diseases health

Healthcare Editors

LEXINGTON, Mass.

infections conditions

sores conditions

wsw.

skin prevention

sores cold

indevus.

conditions hsv

These risks and uncertainties are set
forth in the Company's filings under the Securities Act of 1933 and
the Securities Exchange Act of 1934 under "Risk Factors" and
elsewhere, and include, but are not limited to: dependence on the
success of SANCTURA(TM) and SANCTURA XR(TM); the early stage of
products under development; uncertainties relating to clinical trials,
regulatory approval and commercialization of our products ,
particularly SANCTURA and SANCTURA XR; risks associated with
contractual agreements, particularly for the manufacture and
co-promotion of SANCTURA and SANCTURA XR; dependence on third parties
for manufacturing and marketing; competition; need for additional
funds and corporate partners, including for the development of our
products; failure to acquire and develop additional product
candidates; history of operating losses and expectation of future
losses; product liability and insurance uncertainties; risks relating
to the Redux-related litigation; limited patent and proprietary
rights; dependence on market exclusivity; valuation of our Common
Stock; risks related to repayment of debts; risks related to increased
leverage; and other risks.

prevention diseases

The Company's
presentation will be web cast live and may be accessed by visiting
http://www.indevus.

cold pure

herbal sexually

com/webcast/wfc/idev. (NASDAQ: IDEV) today announced that it will
present at the Friedman Billings Ramsey 9th Annual Growth Conference
on Wednesday , June 1, 2005 at 4:00 p. The Company currently markets SANCTURA(R) for
overactive bladder and has multiple compounds in clinical development,
including PRO 2000 for the prevention of infection by HIV and other
sexually transmitted pathogens, pagoclone for stuttering, aminocandin
for systemic fungal infections, and IP 751 for interstitial cystitis.

transmitted skin

eastern time.com

Indevus Pharmaceuticals is a biopharmaceutical company engaged in
the acquisition, development and commercialization of products
targeting certain medical specialty areas, including urology and
infectious diseases.

shopping treat

genital sexually

----Indevus
Pharmaceuticals, Inc. A link to this site will also be
provided on the Investors section of the Indevus website,
http://www.

daily transmitted

m. eastern time.